Literature DB >> 2103504

TGF alpha in normal physiology.

J E Kudlow1, J D Bjorge.   

Abstract

This paper reviews our work on the localization of transforming growth factor-alpha (TGF alpha) in normal adult tissues and the regulation of its synthesis and that of its receptor. We detected TGF alpha immunohistochemically in brain neurons and showed the TGF alpha mRNA derived from the human brain stem is virtually identical to the mRNA derived from human renal tumour cells. In cells derived from anterior pituitary glands, another site of TGF alpha expression, TGF alpha secretion and mRNA levels can be regulated by phorbol esters. The expression of the epidermal growth factor (EGF) receptor, which is also the TGF alpha receptor, is also stimulated by phorbol esters. Similar stimulation of receptor and ligand expression in human breast cancer cells was shown in response to phorbol esters and EGF. The ability of ligand to stimulate its own synthesis and that of its receptor suggests the presence of an autocrine positive feedback loop, however we were unable to break this loop in the breast cancer cells by antibodies that blocked the interaction of TGF alpha with the EGF receptor. The ability of EGF to stimulate EGF receptor and TGF alpha expression appears to require protein kinase C, since inhibition of this enzyme blocked the ability of EGF to stimulate these genes. These studies raise the possibility that hormones capable of activating protein kinase C could stimulate EGF receptor and TGF alpha expression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2103504

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  2 in total

1.  The role of growth regulatory aberrations in progression of human colon carcinoma.

Authors:  G M Howell; L Sun; B L Ziober; S P Wu; M G Brattain
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

Review 2.  Perinatal factors increase breast cancer risk.

Authors:  L Hilakivi-Clarke; R Clarke; M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.